{
  "source_pdf": "data/clinical_files/Liu et al. (2024).pdf",
  "blocks": [
    {
      "id": "780f7477",
      "page_index": 0,
      "role": "Text",
      "bbox": [
        902.0361328125,
        1464.40673828125,
        2323.650390625,
        2614.31982421875
      ],
      "text": "p\ng\np\nmbinant or cell culture-based\ned inﬂuenza vaccines\nFeng Liu\n1, F. Liaini Gross1, Sneha Joshi1, Manjusha Gaglani\n2,3,4,\nAllison L. Naleway5, Kempapura Murthy4, Holly C. Groom5, Meredith G. Wesley1,6\nLaura J. Edwards6, Lauren Grant1, Sara S. Kim1, Suryaprakash Sambhara1,\nShivaprakash Gangappa\n1, Terrence Tumpey1, Mark G. Thompson1,\nAlicia M. Fry1, Brendan Flannery\n1, Fatimah S. Dawood1 & Min Z. Levine\n1\nRepeat vaccination with egg-based inﬂuenza vaccines could preferentially\nboost antibodies targeting the egg-adapted epitopes and reduce immuno-\ngenicity to circulating viruses. In this randomized trial (Clinicaltrials.gov:\nNCT03722589), sera pre- and post-vaccination with quadrivalent inactivated\negg-based (IIV4), cell culture-based (ccIIV4), and recombinant (RIV4) inﬂuenza\nvaccines were collected from healthcare personnel (18-64 years) in 2018−19\n(N = 723) and 2019−20 (N = 684) inﬂuenza seasons We performed an",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.979656457901001,
        "detection_dpi": 300
      }
    },
    {
      "id": "0daf2127",
      "page_index": 0,
      "role": "Title",
      "bbox": [
        118.62943267822266,
        456.0648193359375,
        2298.305419921875,
        948.4994506835938
      ],
      "text": "year 1, but there was no signiﬁcant difference in HA stalk antibody fold rise\namong vaccine groups in either year 1 or year 2. Multiple seasons of non-eg\nbased vaccination may be needed to redirect antibody responses from\nimmune memory to egg-adapted epitopes and re-focus the immune respons\ntowards epitopes on the circulating viruses to improve vaccine effectivenes\nInﬂuenza viruses are a common cause of respiratory infections in\nhumans, annual inﬂuenza vaccination has been recommended in the\ni\nd S\n( S) f\nd\nd\nC\ni\nll\ni ﬂ\nmanufacturing process can lead to egg-adapted mutations in t\nhemagglutinin (HA) protein in IIV, that could result in altered an\ni i\nd\nd\nd\ni\nff\ni\n(\n)\ni\nh\ni\nl\ni",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9263907074928284,
        "detection_dpi": 300
      }
    },
    {
      "id": "91229ccc",
      "page_index": 0,
      "role": "Text",
      "bbox": [
        1277.6746826171875,
        2738.1748046875,
        2344.081298828125,
        2968.885009765625
      ],
      "text": "https://doi.org/10.1038/s41467-023-44551-x\nesponses from egg-",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9917016625404358,
        "detection_dpi": 300
      }
    },
    {
      "id": "ad024964",
      "page_index": 0,
      "role": "Text",
      "bbox": [
        161.4512939453125,
        2741.572998046875,
        1231.8458251953125,
        2972.909912109375
      ],
      "text": "Article\nRedirecting antibody",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9894729256629944,
        "detection_dpi": 300
      }
    },
    {
      "id": "322dfb5c",
      "page_index": 0,
      "role": "Text",
      "bbox": [
        146.07569885253906,
        3060.50341796875,
        1363.2374267578125,
        3096.19921875
      ],
      "text": null,
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9533048868179321,
        "detection_dpi": 300
      }
    },
    {
      "id": "36f5ef49",
      "page_index": 0,
      "role": "List",
      "bbox": [
        902.1428833007812,
        1080.2816162109375,
        2354.305908203125,
        1359.3499755859375
      ],
      "text": "A(H3N2) immunogenicity. In year 1, RIV4 induced higher neutralizing and total\nHA head binding antibodies to cell- A(H3N2) virus than ccIIV4 and IIV4. In year\n2, among the 7 repeat vaccination arms (IIV4-IIV4, IIV4-ccIIV4, IIV4-RIV4, RIV4-\nccIIV4, RIV4-RIV4, ccIIV4-ccIIV4 and ccIIV4-RIV4), repeat vaccination with\neither RIV4 or ccIIV4 further improved antibody responses to circulating\ni\ni h d\nd\nli i\nib d\n/\nll\ni\nRIV4 l\nh d",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.5371749401092529,
        "detection_dpi": 300
      }
    },
    {
      "id": "3b1dc510",
      "page_index": 1,
      "role": "Figure",
      "bbox": [
        264.77215576171875,
        1711.028076171875,
        2254.40576171875,
        2951.77001953125
      ],
      "text": "[FIGURE 3 - See figure_p2_3b1dc510.png]",
      "html": null,
      "image_path": "figures/figure_p2_3b1dc510.png",
      "metadata": {
        "score": 0.9977578520774841,
        "detection_dpi": 300
      }
    },
    {
      "id": "5605b8d5",
      "page_index": 1,
      "role": "Text",
      "bbox": [
        172.4807586669922,
        684.52685546875,
        1222.5535888671875,
        1671.8809814453125
      ],
      "text": "during the preceding ﬁve seasons.\nYear 1 (2018-20\nccIIV4 n=283\n18-44 years: n=135\n45-64 years: n=148 \nCompleted day 0 (n=283)\n1 month (n=280) and \n6 months (n=266) visit\nRIV n=198\n18-44 years: n=99\n45-64 years: n=99\nCompleted day 0 (n=19\n1 month (n=196) and\n6 months (n=177) vis\nYear 2: Year 1 participan\nIIV4 in Year 1\nn=318 (*139)\nRe-randomized to ccIIV4, RIV4, or IIV4\nn=318 (*139)\nYear 1: 2018-2019\nYear 2: 2019-2020",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9922806620597839,
        "detection_dpi": 300
      }
    },
    {
      "id": "151f2b8c",
      "page_index": 1,
      "role": "Text",
      "bbox": [
        1273.2919921875,
        801.153076171875,
        2339.48095703125,
        1673.9410400390625
      ],
      "text": "p\ny\nYamagata components remained the same (Table 1).\nEnrolled and Randomized n=723\naccine Allocation\nFluzone IIV4 n=122\n18-44 years: n=57\n45-64 years: n=65\nCompleted day 0 (n=110)\n1 month (n=110) and \n6 months (n=101) visit\nFluarix IIV4 n=120\n18-44 years: n=55\n45-64 years: n=65\nCompleted day 0 (n=120)\n1 month (n=118) and \n6 months (n=107) visit \ne-enrolled in Year 2 and new enrollees randomized n=684 (139*)\nccIIV4 in Year 1\nn=214\nRIV4 in Year 1\nn=152",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9732629656791687,
        "detection_dpi": 300
      }
    },
    {
      "id": "b42ff5e7",
      "page_index": 1,
      "role": "Text",
      "bbox": [
        160.6088409423828,
        190.602294921875,
        1233.4600830078125,
        669.8445434570312
      ],
      "text": "IIV4-ccIIV4\nn=106 (*51)\nIIV4-RIV4\nn=104 (*44)\nIIV4-IIV4\nn=103 (*41)\nExcluded n=5\nDid not meet per protocol criteria\nFig. 1 | CONSORT diagrams for screening and Enrollment of participants in Year\n1 (2018−2019) and Year 2 (2019−2020). Abbreviations: IIV4: Inactivated inﬂuenza\nvaccine (Fluzone® or Fluarix® Quadrivalent); ccIIV4: Cell-culture based IIV",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9946849346160889,
        "detection_dpi": 300
      }
    },
    {
      "id": "8d91b87c",
      "page_index": 1,
      "role": "Text",
      "bbox": [
        1274.0469970703125,
        190.86959838867188,
        2340.922119140625,
        650.7365112304688
      ],
      "text": "RIV4-RIV4\nn=74\nccIIV4-RIV4\nn=106\nccIIV4-ccIIV4\nn=101\nRIV4-ccIIV4\nn=73\nExcluded n=12\nDid not meet per protocol criteria\n(Flucelvax® Quadrivalent); RIV4: recombinant-hemagglutinin inﬂuenza vaccine\n(Flublok® Quadrivalent). *Numbers in parenthesis are new enrollees for Year 2.",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9892902970314026,
        "detection_dpi": 300
      }
    },
    {
      "id": "5e27dfe8",
      "page_index": 1,
      "role": "Text",
      "bbox": [
        1258.9229736328125,
        2954.5791015625,
        2332.271728515625,
        3030.3251953125
      ],
      "text": "epitopes could be preferentially boosted from repeat vaccination with\negg-based vaccines3. The potential of non-egg-based vaccines to miti-\nh i\nf\ni\nb\nd\ni\ni\ni\nl\nI\nhi",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9957925081253052,
        "detection_dpi": 300
      }
    },
    {
      "id": "bc31ebbf",
      "page_index": 1,
      "role": "Title",
      "bbox": [
        1276.285888671875,
        686.7272338867188,
        1430.1075439453125,
        736.0327758789062
      ],
      "text": null,
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9970024228096008,
        "detection_dpi": 300
      }
    },
    {
      "id": "73c97565",
      "page_index": 1,
      "role": "Text",
      "bbox": [
        160.27493286132812,
        2956.140869140625,
        1225.8668212890625,
        3072.752685546875
      ],
      "text": "a cell culture based inﬂuenza vaccine (Flucelvax Quadrivalent\nby\nSeqirus, Inc., ccIIV4) and a recombinant inﬂuenza vaccine (Flublok\nQuadrivalent® by SanoﬁPasteur, RIV4). RIV4 contains 3 times the\nd\n/d\n/\nd\nh\nd\nd d",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9830235838890076,
        "detection_dpi": 300
      }
    },
    {
      "id": "0702adab",
      "page_index": 2,
      "role": "Table",
      "bbox": [
        157.49490356445312,
        292.814208984375,
        2343.0068359375,
        1815.122802734375
      ],
      "text": "[TABLE 2 - See table_p3_0702adab.png]",
      "html": null,
      "image_path": "figures/table_p3_0702adab.png",
      "metadata": {
        "score": 0.980256199836731,
        "detection_dpi": 300
      }
    },
    {
      "id": "4606bbf6",
      "page_index": 2,
      "role": "Text",
      "bbox": [
        163.74278259277344,
        2299.551513671875,
        1225.662109375,
        3057.347900390625
      ],
      "text": "gg\nthe study\nViruses\nAmino acids difference\nA(H1N1)pdm09\n45\n74\n120\nYear 1\nA/Michigan/45/2015 cell a\nR\nS\nT\nA/Michigan/45/2015 egg\nR\nS\nT\nA/Michigan/45/2015 X-275 egg CVV\n(EPI830246) b\nR\nS\nT\nA/Singapore/GP1908/2015 IVR-180 egg\nCVV (EPI848715) c,d\nR\nS\nA\nYear 2\nA/Idaho/07/2018 cell a,d\nR\nR\nT\nA/Brisbane/02/2018 egg b\nG\nR\nT\nA(H3N2)\n91\n121\n128\nYear 1\nA/Singapore/INFIMH-16-0019/2016 cell a\nS\nK\nT\nA/Singapore/INFIMH-16-0019/2016 egg\nS\nK\nT\nA/Singapore/INFIMH-16-0019/2016 IVR-186\negg CVV (EPI1082512) b\nS\nK\nT",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9942915439605713,
        "detection_dpi": 300
      }
    },
    {
      "id": "b957e0e3",
      "page_index": 2,
      "role": "Text",
      "bbox": [
        1273.79296875,
        2428.390380859375,
        2336.95654296875,
        3053.49609375
      ],
      "text": "n the HA head domain\n164\n183\n209\n223\n225\n282\n295\n298\nS\nS\nK\nQ\nG\nP\nI\nI\nS\nS\nK\nR\nG\nP\nI\nI\nS\nS\nM\nR\nG\nP\nI\nI\nS\nS\nK\nQ\nA\nP\nI\nI\nT\nP\nK\nQ\nG\nP\nV\nI\nT\nP\nK\nR\nG\nA\nV\nV\n138\n142\n144\n158\n159\n160\n171\n190\n193\n194\n225\n246\n311\nA\nG\nS\nN(CHO)\nY\nT\nK\nD\nF\nL\nD\nN\nH",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9902369379997253,
        "detection_dpi": 300
      }
    },
    {
      "id": "d474d613",
      "page_index": 2,
      "role": "Text",
      "bbox": [
        170.04727172851562,
        1833.3709716796875,
        1863.5150146484375,
        2122.408935546875
      ],
      "text": "Year 2\nA/Kansas/14/2017 cell a,d\nN\nN\nA\nS\nG\nK\nN(CHO-)\nS\nK\nN\nA/Kansas/14/2017 egg b\nN\nN\nA\nS\nG\nK\nN(CHO-)\nS\nK\nN\nB/Victoria lineage\n129\n197\n199\nYear 1\n& 2\nB/Colorado/06/2017 cell\nG\nN\nT\nB/Colorado/06/2017 egg\nG\nT(CHO-)\nT\nB/Maryland/15/2016 BX-69A egg CVV\n(EPI1061863) b,c\nD\nN(CHO-)\nI",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9576026797294617,
        "detection_dpi": 300
      }
    },
    {
      "id": "ede7e14c",
      "page_index": 2,
      "role": "Title",
      "bbox": [
        167.07704162597656,
        2208.5859375,
        1227.511962890625,
        2285.447998046875
      ],
      "text": "A/Singapore/INFIMH-16-0019/2016 NIB-104\negg CVV (EPI1151864) c\nS\nK\nT",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9828110933303833,
        "detection_dpi": 300
      }
    },
    {
      "id": "827ebba1",
      "page_index": 2,
      "role": "Title",
      "bbox": [
        1264.80859375,
        2346.0068359375,
        2325.38330078125,
        2424.443115234375
      ],
      "text": "A\nG\nS\nN(CHO-)\nY\nK\nK\nD\nF\nP\nD/G¶\nN\nH\nA\nG\nS\nN(CHO )\nY\nK\nK\nD\nF\nP\nG\nN\nH",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9380667209625244,
        "detection_dpi": 300
      }
    },
    {
      "id": "feac388e",
      "page_index": 2,
      "role": "Text",
      "bbox": [
        1255.7655029296875,
        2208.133544921875,
        2347.13427734375,
        2298.882080078125
      ],
      "text": "A\nG\nS\nN(CHO-)\nY\nK\nK\nD\nF\nP\nG\nN\nH",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9339773058891296,
        "detection_dpi": 300
      }
    },
    {
      "id": "09247097",
      "page_index": 2,
      "role": "Text",
      "bbox": [
        175.2311248779297,
        200.86123657226562,
        2310.5107421875,
        288.8309326171875
      ],
      "text": "motif at HA position 197; whereas egg-based B/Yamagata vaccine had\nantibody responses to both egg- (GMT 122) and cell- (GMT 137",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.8908219933509827,
        "detection_dpi": 300
      }
    },
    {
      "id": "f4865143",
      "page_index": 3,
      "role": "Figure",
      "bbox": [
        206.65919494628906,
        176.56361389160156,
        2258.2587890625,
        1470.3223876953125
      ],
      "text": "[FIGURE 1 - See figure_p4_f4865143.png]",
      "html": null,
      "image_path": "figures/figure_p4_f4865143.png",
      "metadata": {
        "score": 0.9909664392471313,
        "detection_dpi": 300
      }
    },
    {
      "id": "cf295da8",
      "page_index": 3,
      "role": "Text",
      "bbox": [
        1297.8765869140625,
        2159.359619140625,
        2330.461669921875,
        3093.485107421875
      ],
      "text": "45-64 yrs egg virus\n45-64 yrs cell virus\nDay 0\n1 m\n6 m\n5\n10\n20\n40\n80\n160\n320\n640\n1280\n2560\n5120\n0.045\n0.0046\n<0.0001\n0.03\n0.0074\nDay 0\n1 m\n6 m\n5\n10\n20\n40\n80\n160\n320\n640\n1280\n2560\n5120\nFluzone IIV4\nFluarix IIV4\nccIIV4\nRIV4\n<0.0001\n<0.0001\n<0.0001\n<0.0001\n<0.0001\n0.004\nDay 0\n1 m\n6 m\n5\n10\n20\n40\n80\n160\n320\n640\n1280\n2560\n5120\n0.0041\n0.0072\nDay 0\n1 m\n6 m\n5\n10\n20\n40\n80\n160\n320\n640\n1280\n2560\n5120\n0.032\n0.0009\n0.0165\n5\n10\n20\n40\n80\n160\n320\n640\n1280\n2560\n5120\n5\n10\n20\n40\n80\n160\n320\n640\n1280\n2560\n5120",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9786108136177063,
        "detection_dpi": 300
      }
    },
    {
      "id": "75c30643",
      "page_index": 3,
      "role": "Text",
      "bbox": [
        170.4910430908203,
        1925.671875,
        1232.6607666015625,
        2554.895263671875
      ],
      "text": "B/VIC\nB/YAM\nDay 0\n1 m\n6 m\n5\n10\n20\n40\nHI titer\nDay 0\n1 m\n6 m\n5\n10\n20\n40\nDay 0\n1 m\n6 m\n5\n10\n20\n40\n80\n160\n320\n640\n1280\n2560\n5120\nHI titers (Log2 scale)\nDay 0\n1 m\n6 m\n5\n10\n20\n40\n80\n160\n320\n640\n1280\n2560\n5120\n40\n80\n160\n320\n640\n1280\n2560\n5120\ners (Log2 scale)\n40\n80\n160\n320\n640\n1280\n2560\n5120\n0.035\n0.019\n0",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.993607759475708,
        "detection_dpi": 300
      }
    },
    {
      "id": "b1615215",
      "page_index": 3,
      "role": "Text",
      "bbox": [
        166.80850219726562,
        2565.702392578125,
        1209.4061279296875,
        3104.525146484375
      ],
      "text": "A(H3N2)\nA(H1N1)pdm09\n18-44 yrs egg virus\n18-44 yrs cell virus\nDay 0\n1 m\n6 m\n5\n10\n20\n40\n80\n160\n320\n640\n1280\n2560\n5120\nMN titers (Log2 scale)\n0.003\n0.014\n<0.0001\n0.0008\n0.044\n<0.0001\nDay 0\n1 m\n6\n5\n10\n20\n40\n80\n160\n320\n640\n1280\n2560\n5120\n0.0024\n<0.0001\n<0.0001\n0.008\n0\n80\n160\n320\n640\n1280\n2560\n5120\n(Log2 scale)\n0.02\n80\n160\n320\n640\n1280\n2560\n5120\n0.003",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9968560934066772,
        "detection_dpi": 300
      }
    },
    {
      "id": "aeb5ab4a",
      "page_index": 3,
      "role": "Text",
      "bbox": [
        1281.4044189453125,
        1499.2889404296875,
        2352.5966796875,
        1840.5050048828125
      ],
      "text": "Day 0\n1 m\n6 m\nDay 0\n1 m\n6 m\nccIIV4 45−64 years: Day 0 (n = 148), 1 m (n = 147), 6 m (n = 142); RIV4 18−44 years:\nDay 0 (n = 99), 1 m (n = 98), 6 m (n = 85); RIV4 45−64 years: Day 0 (n = 98), 1 m\n(n = 98), 6 m (n = 92); Microneutralization titers (MN) were measured for A(H3N2)\nvirus, while hemagglutination inhibition (HI) titers were measured for A(H1N1)\npdm09, B/Victoria (B/VIC), and B/Yamagata (B/YAM) viruses. One-way ANOVA\ncorrected for multiple comparisons (Tukey’s test) was used to compare the GMTs\nof each time point among the 4 vaccine groups. Statistically signiﬁcant differences",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9820839762687683,
        "detection_dpi": 300
      }
    },
    {
      "id": "142898bc",
      "page_index": 3,
      "role": "Text",
      "bbox": [
        1272.9989013671875,
        1934.9998779296875,
        2352.0810546875,
        2133.167724609375
      ],
      "text": "Day 0\n1 m\n6 m\nDay 0\n1 m\n6 m\n80\n160\n320\n640\n1280\n2560\n5120\n0.018\n80\n160\n320\n640\n1280\n2560\n5120",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9862019419670105,
        "detection_dpi": 300
      }
    },
    {
      "id": "9c019275",
      "page_index": 3,
      "role": "Text",
      "bbox": [
        172.7443389892578,
        1508.3675537109375,
        1240.8201904296875,
        1884.6614990234375
      ],
      "text": "Day 0\n1 m\n6 m\n5\n10\nH\nDay 0\n1 m\n6 m\n5\n10\nFig. 2 | MN or HI Antibody responses to egg- and cell-propagated vaccine\nviruses at pre-vaccination (Day 0), 1-month, and 6-months post-vaccination in\nYear 1. Antibody titers from each of the four vaccine groups were presented as\ngeometric mean titers (GMTs) with 95% conﬁdence interval (CI) respectively for\n18−44 years and 45−64 years age groups. Gray dots represented individual titers.\nFluzone IIV4 18−44 years: Day 0 (n = 52), 1 m (n = 52), 6 m (n = 47); Fluzone IIV4 45-\n64 years: Day 0 (n = 58), 1 m (n = 58), 6 m (n = 54); Fluarix IIV4 18−44 years: Day 0",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9538711309432983,
        "detection_dpi": 300
      }
    },
    {
      "id": "dca5161e",
      "page_index": 4,
      "role": "Figure",
      "bbox": [
        242.04664611816406,
        187.2356719970703,
        2250.42822265625,
        924.9627685546875
      ],
      "text": "[FIGURE 1 - See figure_p5_dca5161e.png]",
      "html": null,
      "image_path": "figures/figure_p5_dca5161e.png",
      "metadata": {
        "score": 0.9968084692955017,
        "detection_dpi": 300
      }
    },
    {
      "id": "72ba682a",
      "page_index": 4,
      "role": "Text",
      "bbox": [
        1275.636962890625,
        1667.419921875,
        2342.111083984375,
        2825.580322265625
      ],
      "text": "A(H1N1)pdm09 and B/Yamagata, the post-vaccination HI antibody\nGMT egg/cell titer ratios were all <2 and similar (p > 0.05) among the\nvaccine groups (Fig. 5A, B). For B/Victoria, the post-vaccination HI GMT\negg/cell titer ratios were slightly elevated (range: 2−3) with the ratio in\nFluzone IIV4 recipients signiﬁcantly higher (p < 0.05) than those in\n0\n1\n0\n1\n2\n3\n4\n45-64 years\n0.002\n0.003\n0.036\n0.002\n0.0002\n<0.0001\nFluzone IIV4\nFluarix IIV4\nccIIV4\nRIV4\nGeometric mean fold reduction of antibody tit\npost-vaccination (95%CI)\nH3N2 egg\nH3N2 cell\nH1N1 egg\nH1N1 cell\nB/VIC egg\nB/VIC cell\nB/YAM cell\nB/YAM egg\nB/YAM egg\nH3N2 egg\nH3N2 cell\nH1N1 egg\nH1N1 cell\nB/VIC egg\nB/VIC cell\nB/YAM cell\nD\n18−44 years (Fluzone IIV4 (n = 47), Fluarix IIV4 (n = 48), ccIIV4 (n = 124), RIV4\n(n = 85)) and 45−64 years (Fluzone IIV4 (n = 54), Fluarix IIV4 (n = 59), ccIIV4\n(n = 142), RIV4 (n = 92)) respectively (C, D). MN titers were measured for A(H3N2)\nvirus, while HI titers were measured for A(H1N1)pdm09, B/VIC, and B/YAM viruses.\nOne-way ANOVA corrected for multiple comparisons (Tukey’s test) was used to\ncompare the GM fold-rise or fold-reduction of each time point among the 4 vaccine\ngroups. Statistically signiﬁcant differences between groups are indicated by p\nvalues on the horizontal bars.",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9917096495628357,
        "detection_dpi": 300
      }
    },
    {
      "id": "c6e3596b",
      "page_index": 4,
      "role": "Text",
      "bbox": [
        163.68771362304688,
        2211.723388671875,
        1239.8497314453125,
        3001.880859375
      ],
      "text": "0\n1\n2\n3\n4\n5\n6\n18-44 years\n0.0058\n0.0088\n0.0001\n<0.0001\n<0.0001\n<0.0001\n<0.0001\n0.0006\n0.021\n0.047\n0.034\n0.004\n0.005\n0.0035\n0.017\n0.0003\n0.024\n0.01\n0\n1\n2\n3\n4\n5\n6\n45-64 years\nFluzone IIV4\nFluarix IIV4\nccIIV4\nRIV4\nFluzone IIV4\nFluarix IIV4\nccIIV4\nRIV4\n0.0021\n0.0006\n<0.0001\n<0.0001\n<0.0001\n<0.0001\n0.015\n0.0023\n0.0019\n0.002\n0.039\n0.043\n0.0004\n0.03\nGeometric mean fold rise of antibody titers 1-month \npost-vaccination (95%CI)\nH3N2 egg\nH3N2 cell\nH1N1 egg\nH1N1 cell\nB/VIC egg\nB/VIC cell\nB/YAM cell\nB/YAM egg\nH3N2 egg\nH3N2 cell\nH1N1 egg\nH1N1 cell\nB/VIC egg\nB/VIC cell\nB/YAM cell\nB/YAM egg\nA\nB\nFig. 3 | Fold rise of MN or HI antibody titers at 1-month post-vaccination and\nwaning of antibody titers at 6-months post-vaccination in Year 1. Geometric\nmean (GM) fold rise of antibody titers (1 m/Day 0) from each of the four vaccine",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9901891350746155,
        "detection_dpi": 300
      }
    },
    {
      "id": "609127ac",
      "page_index": 4,
      "role": "Text",
      "bbox": [
        169.40090942382812,
        1396.5362548828125,
        1231.876708984375,
        1936.898681640625
      ],
      "text": "Pre-existing A(H3N2) and A(H1N1)pdm09 HA stalk antibodies\nwere detected in participants at varies levels. Comparing HA stalk\nantibody titers at 1-month post-vaccination versus day 0, vaccination\nsigniﬁcantly boosted A(H1N1)pdm09 HA stalk antibodies in all 4 vac-\ncine groups (p < 0.01), and signiﬁcantly boosted A(H3N2) HA stalk\nantibodies in 3 of the 4 vaccine groups (p < 0.001, Fluzone IIV4, ccIIV4,\nand RIV4) (Fig. 4C). The RIV4 group had the highest A(H1N1)pdm09 HA\nstalk and A(H3N2) HA stalk antibodies at 1-month post-vaccination,\nhowever the fold rises of HA stalk antibodies were low (<1.8) and\nsimilar among all 4 vaccine groups (Fig. 4D). At 6-months post-vacci-\nnation, waning of HA stalk antibodies were more notable in ccIIV4 and",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9943084120750427,
        "detection_dpi": 300
      }
    },
    {
      "id": "8ed5be8f",
      "page_index": 4,
      "role": "Text",
      "bbox": [
        1279.5711669921875,
        963.2537841796875,
        2342.62255859375,
        1302.276611328125
      ],
      "text": "participants had GMT egg/cell ratio ≥4 to A(H3N2) and B/Victoria\nviruses, suggesting a high prevalence of pre-existing neutralizing\nantibodies targeting HA egg-adapted epitopes in this highly vaccinated\nHCP population. After vaccination, in both age groups, the two egg-\nbased\nvaccines\ngenerally\nreinforced\nthe\nneutralizing\nantibody\nresponses to egg-adapted epitopes as evidenced by an increased trend\nin the proportion of participants with GMT egg/cell titer ratio ≥4. In\ncontrast, among RIV4 and ccIIV4 recipients, the proportion of parti-",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9846565127372742,
        "detection_dpi": 300
      }
    },
    {
      "id": "b35cb547",
      "page_index": 4,
      "role": "Text",
      "bbox": [
        1276.4840087890625,
        2833.653076171875,
        2336.565185546875,
        3100.254150390625
      ],
      "text": "2\n3\n4\n18-44 years\nFluzone IIV4\nFluarix IIV4\nccIIV4\nRIV4\n0.049\n0.015\n0.03\nWaning-6 month-fold reduction (1m/6m)\ners 6 month \nC",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9924560785293579,
        "detection_dpi": 300
      }
    },
    {
      "id": "11172f20",
      "page_index": 4,
      "role": "Text",
      "bbox": [
        1268.29931640625,
        1401.303955078125,
        2340.14208984375,
        1665.5107421875
      ],
      "text": "RIV4 recipients from the 45−64 years group (Fig. 5B).\nNext, to assess whether vaccination with non-egg-based vaccines\ncan overcome the impact of egg-adaptation and reduce the GMT egg/\ncell ratio in the vaccine responses, we calculated the “proportion of the\nparticipants with egg/cell ratio ≥4” in MN/HI titers at pre- and 1-month\npost-vaccination (Fig. 5C, D). At pre-vaccination, there was no sig-",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.986927330493927,
        "detection_dpi": 300
      }
    },
    {
      "id": "ea97191d",
      "page_index": 4,
      "role": "Text",
      "bbox": [
        169.43739318847656,
        967.5380859375,
        1224.9061279296875,
        1187.751220703125
      ],
      "text": "Antibody responses to egg-adapted epitopes measured by\nantibody GMT egg/cell titer ratio in year 1\nTo assess the levels of antibody responses targeting the egg-adapted\nepitopes, we used the antibody “GMT egg/cell titer ratio” as a proxy to\nquantify the extent of difference in antibody responses to egg- versus",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9898250699043274,
        "detection_dpi": 300
      }
    },
    {
      "id": "cb53abc9",
      "page_index": 4,
      "role": "Text",
      "bbox": [
        170.67796325683594,
        1940.158447265625,
        1235.4541015625,
        2070.216064453125
      ],
      "text": "(n = 98)) age groups respectively (A, B). Antibody waning was expressed as the GM\nfold-reduction of titers from 1-month to 6-months (1 m/6 m) post-vaccination for",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9705444574356079,
        "detection_dpi": 300
      }
    },
    {
      "id": "88398e9b",
      "page_index": 4,
      "role": "Title",
      "bbox": [
        174.42330932617188,
        2117.98388671875,
        1165.5484619140625,
        2208.3046875
      ],
      "text": "(\n)\ny\n(\n/\ny\n)\ngroups were calculated for egg- and cell-propagated vaccine viruses, and for 18\nyears (Fluzone IIV4 (n = 52), Fluarix IIV4 (n = 55), ccIIV4 (n = 133), RIV4 (n = 98))",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9737300872802734,
        "detection_dpi": 300
      }
    },
    {
      "id": "7e8872b4",
      "page_index": 4,
      "role": "Text",
      "bbox": [
        174.0779571533203,
        3013.992919921875,
        1252.0811767578125,
        3099.41845703125
      ],
      "text": "Fl\nIIV4\n1 month-fold rise (1m/Day 0)",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9195493459701538,
        "detection_dpi": 300
      }
    },
    {
      "id": "9da929bc",
      "page_index": 4,
      "role": "Text",
      "bbox": [
        179.97915649414062,
        1272.942138671875,
        1212.819580078125,
        1309.1129150390625
      ],
      "text": "year 1, a total of 26 breakthrough infection cases were identiﬁed with",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.8244516849517822,
        "detection_dpi": 300
      }
    },
    {
      "id": "b0a88f0c",
      "page_index": 5,
      "role": "Figure",
      "bbox": [
        225.00450134277344,
        171.90794372558594,
        2277.38134765625,
        1441.20703125
      ],
      "text": "[FIGURE 1 - See figure_p6_b0a88f0c.png]",
      "html": null,
      "image_path": "figures/figure_p6_b0a88f0c.png",
      "metadata": {
        "score": 0.9638685584068298,
        "detection_dpi": 300
      }
    },
    {
      "id": "6b103e88",
      "page_index": 5,
      "role": "Text",
      "bbox": [
        1277.675048828125,
        2064.890625,
        2332.037841796875,
        2775.057373046875
      ],
      "text": "Day 0\n1 m\n6 m\n200\n400\n800\n1600\n3200\n6400\nFluzone IIV4\nFluarix IIV4\nccIIV4\nRIV4\n0.02\n0.043\n0.0046\n0.007\n0.038\n<0.000\n1\n0.044\n*\n*\n*\nDay 0\n1 m\n6 m\n200\n400\n800\n1600\n3200\n6400\n12800\n25600\n0.0036\n<0.0001\n0.03\n0.0003\n0.0017\n<0.0001\n0.016\n<0.0001\n0.0063\n0.024\n*\n*\n*\n*\n4\nG\nC\nELISA titers (Log2 scale)\nELISA titers (Log2 scale)\nrise of  \n(95% CI)\nH3 stalk\nH1 stalk\nD\n6 m\n0.049\n0.015\n6 m\n0.0016\n0.0039\n<0.0001\n0.0003\nHA stalk ELISA titer fold-rise \n(1m/day0)",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.986150324344635,
        "detection_dpi": 300
      }
    },
    {
      "id": "aab3768e",
      "page_index": 5,
      "role": "Text",
      "bbox": [
        168.89773559570312,
        2559.10888671875,
        1220.575439453125,
        3099.64404296875
      ],
      "text": "A(H3N2)\nA(H1N1)pdm09\nEgg virus HA\nCell vir\nELISA titers (Log2 scale)\ners (Log2 scale)\nA\nDay 0\n1 m\n400\n800\n1600\n3200\n6400\n12800\n25600\n51200\n0.006\n<0.000\n<0.00\n3200\n6400\n12800\n25600\n51200\n0.047\n0.0001\n0.0065\n<0.0001\n0.014\n<0.0001\n0.0082\n<0.0001\n0.0028\n0.0055\n0.0004\n0.03\n3200\n6400\n12800\n25600\n51200\n0.0063\n0.0011\n0.0066\n<0.00\n0.01\n<0.\nDay 0\n1 m\n6 m\n400\n800\n1600\n3200\n6400\n12800\n25600\n51200\n0.047\n0.0037\n0.032\n0.032\n0.002\n0.013\n0.014",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9953328967094421,
        "detection_dpi": 300
      }
    },
    {
      "id": "ca5a2586",
      "page_index": 5,
      "role": "Text",
      "bbox": [
        1266.1763916015625,
        1471.9742431640625,
        2352.711669921875,
        1932.8984375
      ],
      "text": "0\n1\nGeome\nELISA tite\nH3 stalk\nH1 stalk\n6 m\ncorrected for multiple comparisons (Tukey’s test) was used to compare the GMTs\nof each time point among the 4 vaccine groups (A, C). One-way ANOVA nonpara-\nmetric Kruskal-Wallis test was used to compare the fold changes among the 4\nvaccine groups (B, D). Statistically signiﬁcant differences between groups are\nindicated by p values on the horizontal bars.*: In (C), paired t test (two-tailed) was\nused for comparing the pre- and 1 m post-vaccination stalk antibody titers within\nthe same vaccine group: signiﬁcantly higher HA stalk antibody titers were detected\nin 1 m post-vaccination than pre-vaccination for H3 stalk binding antibody in Flu-\none IIV4 (p\n0 0009) ccIIV4 (p\n0 0004) RIV4 (p < 0 0001); and for H1 stalk",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.977258026599884,
        "detection_dpi": 300
      }
    },
    {
      "id": "a2bfedeb",
      "page_index": 5,
      "role": "Text",
      "bbox": [
        1276.8125,
        2781.5751953125,
        2339.28955078125,
        3093.802734375
      ],
      "text": "A\nGeometric mean ratio of  ELISA \ntiter egg/cell HA (95% CI)\nB\nH3 HA\nH1 HA\nB/VIC HA\nB/YAM HA\n6 m\nFluzone IIV4\nFluarix IIV4\nccIIV4\nRIV4\n02\n<0.0001\n0.0002\n0\n1\n2\n3\n4\nFluzone IIV4\nFluarix IIV4\nccIIV4\nRIV4\n0.009\n<0.0001\n<0.0001\n0.002\n0.041\n0.03\n0.006\n0.016\nEgg/Cell HA ELISA titer ratio (1m)",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9941117167472839,
        "detection_dpi": 300
      }
    },
    {
      "id": "c409ac0c",
      "page_index": 5,
      "role": "Text",
      "bbox": [
        174.3904571533203,
        2380.285400390625,
        1226.186767578125,
        2549.688720703125
      ],
      "text": "ELISA tit\n)\nDay 0\n1 m\n6 m\n400\n800\n1600\nDay 0\n1 m\n400\n800\n1600\n51200\n0.019\n<0.0001\n<0.0001\n0.0088\n0.0004\n0.0007\n0.036\n0.015\n51200\n0.0011\n<0.0001\n0.0011\n0.005\n0.02\n<",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.987641453742981,
        "detection_dpi": 300
      }
    },
    {
      "id": "62c80c9f",
      "page_index": 5,
      "role": "Text",
      "bbox": [
        171.59268188476562,
        1580.313232421875,
        1223.4591064453125,
        1832.4696044921875
      ],
      "text": "Fig. 4 | Total HA binding antibody and HA stalk antibody responses measured\nby ELISA at pre-vaccination (Day 0), 1-month, and 6-months post-vaccination\nin Year 1. Antibody titers from each of the four vaccine groups were presented as\ngeometric mean titers (GMTs) with 95% conﬁdence interval (CI) for combined\n18−44 years and 45−64 years age groups. Gray dots represented individual titers.\nFluzone IIV4: Day0 (n = 24), 1 m (n = 24), 6 m (n = 21); Fluarix IIV4: Day 0 (n = 24), 1 m",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9640598893165588,
        "detection_dpi": 300
      }
    },
    {
      "id": "ad9f2327",
      "page_index": 5,
      "role": "Text",
      "bbox": [
        179.46832275390625,
        1845.195068359375,
        1215.3375244140625,
        1974.157470703125
      ],
      "text": "ELISA titers\nDay 0\n1 m\n6 m\n400\n800\n1600\n3200\nDay 0\n1\n400\n800\n1600\n3200",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9592411518096924,
        "detection_dpi": 300
      }
    },
    {
      "id": "579d38c9",
      "page_index": 5,
      "role": "Text",
      "bbox": [
        157.60076904296875,
        2076.016357421875,
        1227.7752685546875,
        2204.935546875
      ],
      "text": "ELIS\ne)\nDay 0\n1 m\n6 m\n400\n800\nDay 0\n1 m\n400\n51200\n<0.0001\n<0.0001\n0.0011\n0.0008\n0.0002\n<0.0001\n0.0081\n0.018\n<0.0001\n51200\n<0.0001\n<0.0001\n0.005\n0.004\n<0.0001\n<0.0001\n<",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9463305473327637,
        "detection_dpi": 300
      }
    },
    {
      "id": "69f7ff84",
      "page_index": 5,
      "role": "Text",
      "bbox": [
        160.139404296875,
        1482.6661376953125,
        1233.33837890625,
        1568.744140625
      ],
      "text": "(n = 24), 6 m (n = 23); ccIIV4: Day 0 (n = 56), 1 m (n = 54), 6 m (n = 51); RIV4: Day 0\n(n = 40), 1 m (n = 40), 6 m (n = 38). A: HA (A(H1N1)pdm09) or HA head (A(H3N2), B/",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.788158655166626,
        "detection_dpi": 300
      }
    },
    {
      "id": "b3a95400",
      "page_index": 5,
      "role": "Title",
      "bbox": [
        154.52374267578125,
        2252.4873046875,
        1247.3525390625,
        2379.671875
      ],
      "text": "B/VIC\ners (Log2 scale)\n3200\n6400\n12800\n25600\n51200\n3200\n6400\n12800\n25600",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.7111074924468994,
        "detection_dpi": 300
      }
    },
    {
      "id": "d52355c3",
      "page_index": 6,
      "role": "Figure",
      "bbox": [
        202.00221252441406,
        182.20262145996094,
        2269.963623046875,
        1217.7808837890625
      ],
      "text": "[FIGURE 1 - See figure_p7_d52355c3.png]",
      "html": null,
      "image_path": "figures/figure_p7_d52355c3.png",
      "metadata": {
        "score": 0.9950845837593079,
        "detection_dpi": 300
      }
    },
    {
      "id": "9d981e40",
      "page_index": 6,
      "role": "Text",
      "bbox": [
        169.44998168945312,
        1761.1474609375,
        1227.923583984375,
        2558.49609375
      ],
      "text": "A(H3N2)\nA(H1N1)pdm09\nB/VIC\nB/YAM\n f\no\n \noit\na\nr \nn\na\ne\nm\n cirt\ne\nm\no\ne\nG\nB\n0\n1\n2\n3\n4\n5\n6\n45-64 years\nFluzone IIV4\nFluarix IIV4\nccIIV4\nRIV4\n<0.0001\n<0.0001\n0.0084\n0.011\nFig. 5 | Difference in MN or HI antibody responses to egg-adapted epitopes\nstratiﬁed by age groups and vaccine type in Year 1. A, B: Geometric mean ratio\nof egg/cell virus titers at 1-month post-vaccination with 95% CI for each vaccine\ncomponent among the 4 vaccine groups for 18-44 years (A Fluzone IIV4: n = 52,\nFluarix IIV4: n = 55, ccIIV4: n = 133, RIV4: n = 98) and 45−64 years (B Fluzone IIV4:\nn = 58, Fluarix IIV4: n = 63, ccIIV4: n = 147, RIV4: n = 98) age groups. One-way\nANOVA nonparametric Kruskal-Wallis test was used for comparison of geometric",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9935978651046753,
        "detection_dpi": 300
      }
    },
    {
      "id": "5e27d60f",
      "page_index": 6,
      "role": "Text",
      "bbox": [
        1273.9306640625,
        2162.688720703125,
        2341.661865234375,
        2689.416259765625
      ],
      "text": "0\nProportion of ≥4 -fold reduced titer to cell va\n20\n40\n60\n80\n100\n40%\n21%\nFluzone IIV4\nFluarix IIV4\nccIIV4\nRIV4\nA(H3N2)\nA(H1N1)pdm09\nB/VIC\nB/YAM\nPre\nPost\nPre\nPost\nPre\nPost\nPre\nPost\n45-64 years\nD\np=0.005",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9939215183258057,
        "detection_dpi": 300
      }
    },
    {
      "id": "b2ed3635",
      "page_index": 6,
      "role": "Text",
      "bbox": [
        170.66665649414062,
        2581.5546875,
        1205.9298095703125,
        3054.1669921875
      ],
      "text": "A(H3N2)\nA(H1N1)pdm09\nB/VIC\nB/YAM\n)I\nC\n \n%\n5\n9\n( r\ne\ntit s\nu\nriv lle\nc/\ng\ng\nA\n0\n1\n2\n3\n4\n5\n6\nFluzone IIV4\nFluarix IIV4\nccIIV4\nRIV4\n0.0014\n0.0021\n0.03",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9972284436225891,
        "detection_dpi": 300
      }
    },
    {
      "id": "e3cddf12",
      "page_index": 6,
      "role": "Text",
      "bbox": [
        1266.6669921875,
        2702.68408203125,
        2341.548828125,
        3061.202880859375
      ],
      "text": "20\n40\n60\n80\n100\n58%\n26%\nFluzone IIV4\nFluarix IIV4\nccIIV4\nRIV4\nccine virus (egg/cell)\np=0.0001\nA(H3N2)\nA(H1N1)pdm09\nB/VIC\nB/YAM\n18-44 years",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9959157109260559,
        "detection_dpi": 300
      }
    },
    {
      "id": "5cf6ea89",
      "page_index": 6,
      "role": "Text",
      "bbox": [
        1284.033447265625,
        1244.7947998046875,
        2347.778076171875,
        1659.4957275390625
      ],
      "text": "Comparing pre- and 1-month post-vaccination, A(H3N2) HA stalk\nbinding antibodies were signiﬁcantly boosted in ccIIV4-RIV4, RIV4-RIV4,\nIV4-ccIIV4, and IIV4-RIV4 arms, while A(H1N1)pdm09 HA stalk binding\nantibodies were also signiﬁcantly boosted in ccIIV4-ccIIV4 and RIV4-ccIIV4\narms (Fig. 8C). However, fold rise in both A(H1N1)pdm09 HA stalk and\nA(H3N2) HA stalk antibodies were low (GM fold rise <1.78) with no sig-\nniﬁcant difference (p > 0 05) among all 7 repeat vaccination arms (Fig 8D)\ntion (C, D).",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9841457009315491,
        "detection_dpi": 300
      }
    },
    {
      "id": "fb8e6c04",
      "page_index": 6,
      "role": "Text",
      "bbox": [
        174.612548828125,
        1234.8662109375,
        1219.0303955078125,
        1659.7113037109375
      ],
      "text": "A(H3N2) and B/VIC in the 18−44 years group, B/VIC virus and B/YAM\nvirus in the 45−64 years group, suggesting repeated boost to anti\nbodies targeting egg-adapted epitopes in these participants after\nreceiving consecutive egg-based IIV4 vaccination. In contrast, among\nrecipients of non-egg-based vaccines in just one study year (IIV4-ccIIV4\nor IIV4-RIV4) or in both study years (ccIIV4-ccIIV4, ccIIV4-RIV4, RIV4\nccIIV4, RIV4-RIV4), the proportions of participants with egg/cell ratio\neach vaccine group. Proportions of participants who had ≥4 -fold reduced titer to",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9757872819900513,
        "detection_dpi": 300
      }
    },
    {
      "id": "0f7cc72a",
      "page_index": 6,
      "role": "Text",
      "bbox": [
        1273.5189208984375,
        1767.9505615234375,
        2340.511962890625,
        2076.617431640625
      ],
      "text": "cell vaccine virus (egg/cell titer ratio) at pre- and 1-month post-vaccination were\npresented for each vaccine component among the 4 vaccine groups for 18−44\nyears (C) and 45−64 years (D). Fisher’s exact test (two-tailed) was performed for\ncomparing proportions of ≥4 -fold reduced titer to cell vaccine virus between pre-\nand 1-month post-vaccination in each vaccine group. MN titers were measured for\nA(H3N2) virus, while HI titers were measured for A(H1N1)pdm09, B/VIC, and B/\nYAM viruses. Statistically signiﬁcant differences between groups are indicated by p",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9860073924064636,
        "detection_dpi": 300
      }
    },
    {
      "id": "a6a42178",
      "page_index": 6,
      "role": "Title",
      "bbox": [
        1276.5408935546875,
        2114.27734375,
        1500.42041015625,
        2159.009033203125
      ],
      "text": "0",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.998230516910553,
        "detection_dpi": 300
      }
    },
    {
      "id": "fe11606f",
      "page_index": 7,
      "role": "Figure",
      "bbox": [
        200.74053955078125,
        175.27784729003906,
        2233.68017578125,
        1482.9990234375
      ],
      "text": "[FIGURE 1 - See figure_p8_fe11606f.png]",
      "html": null,
      "image_path": "figures/figure_p8_fe11606f.png",
      "metadata": {
        "score": 0.9887585639953613,
        "detection_dpi": 300
      }
    },
    {
      "id": "2465f363",
      "page_index": 7,
      "role": "Text",
      "bbox": [
        169.82083129882812,
        2401.474853515625,
        1224.00732421875,
        3103.80810546875
      ],
      "text": "A(H3N2)\nA(H1N1)pdm09\n18-44 yrs egg virus\n18-44 yrs cell virus\nDay 0\n1 m\n5\n10\n20\n40\n80\n160\n320\n640\n1280\n2560\n5120\nHI titers (Log2 scale)\nDay 0\n1 m\n5\n10\n20\n40\n80\n160\n320\n640\n1280\n2560\n5120\n<0.0001\n0.011\n0.013\n<0.0001\nDay 0\n1 m\n5\n10\n20\n40\n80\n160\n320\n640\n1280\n2560\n5120\nHI titers (Log2 scale)\nDay 0\n1 m\n5\n10\n20\n40\n80\n160\n320\n640\n1280\n2560\n5120\n0.02\n0.0011",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9972992539405823,
        "detection_dpi": 300
      }
    },
    {
      "id": "82e72e9a",
      "page_index": 7,
      "role": "Text",
      "bbox": [
        1270.1146240234375,
        2118.2890625,
        2346.926025390625,
        2717.87158203125
      ],
      "text": "Day 0\n1 m\n5\n10\n20\n40\n80\n160\n320\n640\n1280\n2560\n5120\nHI titers (Log2 scale)\nDay 0\n1 m\n5\n10\n20\n40\n80\n160\n320\n640\n1280\n2560\n5120\n0.01\n0.004\n0.01\nDay 0\n1 m\n5\n10\n20\n40\n80\n160\n320\n640\n1280\n2560\n5120\nHI titers (Log2 scale)\nDay 0\n1 m\n5\n10\n20\n40\n80\n160\n320\n640\n1280\n2560\n5120\n0.04\n<0.0001\n0.0006\n<0.0001\n0.03\n0.0002",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9968018531799316,
        "detection_dpi": 300
      }
    },
    {
      "id": "876e133f",
      "page_index": 7,
      "role": "Text",
      "bbox": [
        167.4258575439453,
        1843.3968505859375,
        1222.1998291015625,
        2371.11474609375
      ],
      "text": "B/VIC\nB/YAM\nDay 0\n1 m\n5\n10\n20\n40\n80\n160\n320\n640\n1280\n2560\nHI titers (Log2 scale)\nDay 0\n1 m\n5\n10\n20\n40\n80\n160\n320\n640\n1280\n2560\n0.014\n0.0003\nDay 0\n1 m\n5\n10\n20\n40\n80\n160\n320\n640\n1280\n2560\n5120\nHI titers (Log2 scale)\nDay 0\n1 m\n5\n10\n20\n40\n80\n160\n320\n640\n1280\n2560\n5120\n0.006\n0.0004\n0.0004",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9965896606445312,
        "detection_dpi": 300
      }
    },
    {
      "id": "a94db619",
      "page_index": 7,
      "role": "Text",
      "bbox": [
        1274.1055908203125,
        2736.300048828125,
        2340.3515625,
        3097.85888671875
      ],
      "text": "45-64 yrs egg virus\n45-64 yrs cell virus\nDay 0\n1 m\n5\n10\n20\n40\n80\n160\n320\n640\n1280\n2560\n5120\nHI titers (Log2 scale)\nDay 0\n1 m\n5\n10\n20\n40\n80\n160\n320\n640\n1280\n2560\n5120\nccIIV4-ccIIV4\nccIIV4-RIV4\nRIV4-ccIIV4\nRIV4-RIV4\nIIV4-ccIIV4\nIIV4-RIV4\nIIV4-IIV4\n0.007\n0.0002",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9974566102027893,
        "detection_dpi": 300
      }
    },
    {
      "id": "a13f3437",
      "page_index": 7,
      "role": "Text",
      "bbox": [
        1278.789794921875,
        1493.755615234375,
        2340.610107421875,
        1739.6375732421875
      ],
      "text": "(n\n45), RIV4 RIV4 (n\n44), IIV4 ccIIV4 (n\n57), IIV4 RIV4 (n\n56), IIV4 IIV4 (n\n56).\nUnpaired t test (two-tailed) was used to compare the post-vaccination GMTs to cell\nvaccine viruses between IIV4-IIV4 (Fluzone) arm and each of the remaining 6 vac-\ncine arms within the same age group. Statistically signiﬁcant differences between\ngroups are indicated by p values on the horizontal bars.",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9929116368293762,
        "detection_dpi": 300
      }
    },
    {
      "id": "7360231c",
      "page_index": 7,
      "role": "Text",
      "bbox": [
        1265.8819580078125,
        1846.432861328125,
        2336.829345703125,
        2114.904296875
      ],
      "text": "Day 0\n1 m\n5\n10\n20\n40\n80\n160\n320\n640\n1280\n2560\n5120\nHI titers (Log2 scale)\nDay 0\n1 m\n5\n10\n20\n40\n80\n160\n320\n640\n1280\n2560\n5120\n<0.0001\n0.007\n0.0006\n<0.0001",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9863015413284302,
        "detection_dpi": 300
      }
    },
    {
      "id": "86998ed0",
      "page_index": 7,
      "role": "Text",
      "bbox": [
        168.3289794921875,
        1507.9449462890625,
        1236.9635009765625,
        1777.4141845703125
      ],
      "text": "g\n|\ny\np\ngg\np\np g\npre- and 1-month post-vaccination in year 2 stratiﬁed by 7 repeat\nvaccination arms. HI antibody titers from each of the 7 repeat vaccine arms were\npresented as geometric mean titers (GMTs) with 95% conﬁdence interval (CI)\nrespectively for 18−44 years and 45−64 years age groups. Gray dots represented\nindividual titers. 18−44 years: ccIIV4-ccIIV4 (n = 42), ccIIV4-RIV4 (n = 45), RIV4-\nccIIV4 (n = 28), RIV4-RIV4 (n = 30), IIV4-ccIIV4 (n = 49), IIV4-RIV4 (n = 48), IIV4-IIV4",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9440671801567078,
        "detection_dpi": 300
      }
    },
    {
      "id": "607ba538",
      "page_index": 8,
      "role": "Figure",
      "bbox": [
        205.44796752929688,
        200.66448974609375,
        2221.628662109375,
        1330.7337646484375
      ],
      "text": "[FIGURE 1 - See figure_p9_607ba538.png]",
      "html": null,
      "image_path": "figures/figure_p9_607ba538.png",
      "metadata": {
        "score": 0.9897775053977966,
        "detection_dpi": 300
      }
    },
    {
      "id": "0040f8f5",
      "page_index": 8,
      "role": "Text",
      "bbox": [
        168.6178741455078,
        1613.93505859375,
        1227.220947265625,
        2424.2744140625
      ],
      "text": "IIV4 and ccIIV4 (15 µg HA/dose/strain). For A(H3N2), RIV4 vaccination\nl i\nd h\nli\nf h f\ni\nl\nli i\nib d\nFig. 7 | Dynamics of proportion of participants with HI GMT egg/cell ratio ≥4\nfold among seven repeat vaccination arms in Year 2. Proportions of Year 2\nparticipants who had ≥4 -fold reduced titer to cell vaccine virus (egg/cell titer ratio)\nat pre- and 1-month post-vaccination were presented for each vaccine component\namong the seven Year 1-Year 2 vaccine arms. A: 18-44 years age group and B: 45−64",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9934815168380737,
        "detection_dpi": 300
      }
    },
    {
      "id": "09e2fed5",
      "page_index": 8,
      "role": "Text",
      "bbox": [
        1273.8265380859375,
        2395.817626953125,
        2339.90380859375,
        3088.739013671875
      ],
      "text": null,
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9963957667350769,
        "detection_dpi": 300
      }
    },
    {
      "id": "1310697f",
      "page_index": 8,
      "role": "Text",
      "bbox": [
        1262.91748046875,
        1619.3218994140625,
        2333.294189453125,
        2368.580078125
      ],
      "text": "The impact of egg-adaptation was the least profound on the\nyears age group. Fisher’s exact test (two-tailed) was performed for comparing\nproportions of ≥4 -fold reduced titer to cell vaccine virus between pre- and\n1-month post-vaccination in each vaccine group. P values noted on the corre-\nsponding trend lines indicate statistically signiﬁcant difference of the proportions\nbetween pre- and post-vaccination.",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9886115193367004,
        "detection_dpi": 300
      }
    },
    {
      "id": "2a45e33d",
      "page_index": 8,
      "role": "Text",
      "bbox": [
        168.46995544433594,
        2436.1318359375,
        1224.3250732421875,
        3106.741455078125
      ],
      "text": null,
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9928513765335083,
        "detection_dpi": 300
      }
    },
    {
      "id": "96a180f1",
      "page_index": 8,
      "role": "Text",
      "bbox": [
        179.3647918701172,
        1337.431884765625,
        1262.74951171875,
        1535.0894775390625
      ],
      "text": "years, it also signiﬁcantly increased the quantity of the total A(H3N2)\ncell HA head binding antibodies (Fig. 4A, Fig. S1A). However, for\nA(H1N1)pdm09 and B viruses, the difference in HI antibody versus the\notal HA head binding antibody levels among 4 vaccine groups was less\nconsistent suggesting that the magnitude of improvement differ",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9917460680007935,
        "detection_dpi": 300
      }
    },
    {
      "id": "7c01762d",
      "page_index": 8,
      "role": "Text",
      "bbox": [
        1269.6209716796875,
        1335.7042236328125,
        2351.50244140625,
        1532.7230224609375
      ],
      "text": "have reported that Q223R egg-adapted change at the HA head domain\nof A(H1N1)pdm09 virus can promote virus replication in eggs, alter\nantigenicity and inﬂuence immune response37–42. In this study, 1-month\npost-vaccination GMTs to both egg- and cell-propagated A(H1N1)\npdm09 vaccine viruses in year 1 were similar among the 4 vaccine",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9733071327209473,
        "detection_dpi": 300
      }
    },
    {
      "id": "90bee6e4",
      "page_index": 9,
      "role": "Figure",
      "bbox": [
        237.9291229248047,
        167.11822509765625,
        2279.707275390625,
        1483.7379150390625
      ],
      "text": "[FIGURE 1 - See figure_p10_90bee6e4.png]",
      "html": null,
      "image_path": "figures/figure_p10_90bee6e4.png",
      "metadata": {
        "score": 0.9871336221694946,
        "detection_dpi": 300
      }
    },
    {
      "id": "10c518cc",
      "page_index": 9,
      "role": "Text",
      "bbox": [
        170.03964233398438,
        2105.32958984375,
        1220.322021484375,
        2878.2109375
      ],
      "text": "A(H1N1)pdm09\nB/VIC\nDay 0\n1 m\n400\n800\n1600\nELISA tit\nDay 0\n1 m\n400\n800\n1600\nDay 0\n1 m\n400\n800\n1600\n3200\n6400\n12800\n25600\n51200\nELISA titers (Log2 scale)\nDay 0\n1 m\n400\n800\n1600\n3200\n6400\n12800\n25600\n51200\nDay 0\n1 m\n400\n800\n1600\n3200\n6400\n12800\n25600\n51200\nELISA titers (Log2 scale)\nDay 0\n1 m\n400\n800\n1600\n3200\n6400\n12800\n25600\n51200\n0.00",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9938327074050903,
        "detection_dpi": 300
      }
    },
    {
      "id": "586b09ff",
      "page_index": 9,
      "role": "Text",
      "bbox": [
        1282.818115234375,
        2103.065185546875,
        2332.67724609375,
        2738.06982421875
      ],
      "text": "Day 0\n1 m\n200\n400\n800\n1600\n3200\n6400\nELISA titers (Log2 scale)\nIIV4-ccIIV4\nIIV4-RIV4\nIIV4-IIV4\nccIIV4-ccIIV4\nccIIV4-RIV4\nRIV4-ccIIV4\nRIV4-RIV4\n*\n*\n*\n*\nDay 0\n1 m\n200\n400\n800\n1600\n3200\n6400\n12800\n25600\nELISA titers (Log2 scale)\n0.037\n0.037\n0.017\n*\n*\nH3 stalk\nH1 stalk\nA \nC\nD",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9873315691947937,
        "detection_dpi": 300
      }
    },
    {
      "id": "cb9c94ec",
      "page_index": 9,
      "role": "Text",
      "bbox": [
        1271.436767578125,
        2740.95751953125,
        2345.38623046875,
        3099.45361328125
      ],
      "text": "B\n0\n1\n2\n3\n4\nccIIV4-ccIIV4\nccIIV4-RIV4\nRIV4-ccIIV4\nRIV4-RIV4\nIIV4-ccIIV4\nIIV4-RIV4\nIIV4-IIV4\nH3 HA\nH1 HA\nB/VIC HA\nB/YAM HA\nGeometric mean ratio of  ELISA \ntiter egg/cell HA (95% CI)\nccIIV4-ccIIV4\nccIIV4-RIV4\nRIV4-ccIIV4\nRIV4-RIV4\nIIV4-ccIIV4\nIIV4-RIV4\nIIV4-IIV4\nEgg/cell HA ELISA \u0002ter ra\u0002o (1m)",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9934691190719604,
        "detection_dpi": 300
      }
    },
    {
      "id": "bcb4fe5b",
      "page_index": 9,
      "role": "Text",
      "bbox": [
        1288.7840576171875,
        1524.6497802734375,
        2324.46337890625,
        1973.6715087890625
      ],
      "text": "0\n1\n2\nRIV4-ccIIV4\nRIV4-RIV4\nIIV4-ccIIV4\nIIV4-RIV4\nIIV4-IIV4\nH3 stalk\nH1 stalk\nGeometric mean fold\ntiters to HA stal\nwithin the same age group (A). One-way ANOVA corrected for multiple compar-\nsons (Tukey’s test) was used to compare the GMTs of stalk binding antibody at\neach time point among the 4 vaccine groups (C). One-way ANOVA nonparametri\nKruskal-Wallis test was used to compare the fold changes among the 4 vaccine\ngroups (B, D).Statistically signiﬁcant differences between groups are indicated by p\nvalues on the horizontal bars (A, C). *In (C), paired t test (two-tailed) was used fo",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9817034602165222,
        "detection_dpi": 300
      }
    },
    {
      "id": "ce1e37d3",
      "page_index": 9,
      "role": "Text",
      "bbox": [
        171.9923553466797,
        2883.178466796875,
        1226.052001953125,
        3103.513916015625
      ],
      "text": "A(H3N2)\nA\nEgg virus HA\nCell virus HA\n3200\n6400\n12800\n25600\n51200\ners (Log2 scale)\n3200\n6400\n12800\n25600\n51200\n0.039",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9960975050926208,
        "detection_dpi": 300
      }
    },
    {
      "id": "fa38b393",
      "page_index": 9,
      "role": "Text",
      "bbox": [
        175.32908630371094,
        1905.5379638671875,
        1219.337158203125,
        2024.0172119140625
      ],
      "text": "B/YAM\n3200\n6400\n12800\n25600\niters (Log2 sca\n3200\n6400\n12800\n25600",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9828753471374512,
        "detection_dpi": 300
      }
    },
    {
      "id": "68d47cb0",
      "page_index": 9,
      "role": "Text",
      "bbox": [
        163.10400390625,
        1523.1998291015625,
        1230.7152099609375,
        1713.9696044921875
      ],
      "text": "pre- and 1-month post-vaccination in 7 repeat vaccination arms. Antibody titers\nfrom each of the 7 vaccine arms were presented as geometric mean titers (GMTs)\nwith 95% conﬁdence interval (CI) for combined 18−44 years and 45−64 years age\ngroups. Gray dots represented individual titers. ccIIV4-ccIIV4 (n = 20), ccIIV4-RIV4\n(n = 22), RIV4-ccIIV4 (n = 16), RIV4-RIV4 (n = 16), IIV4-ccIIV4 (n = 22), IIV4-RIV4",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.973629891872406,
        "detection_dpi": 300
      }
    },
    {
      "id": "3d6e6a6b",
      "page_index": 10,
      "role": "Text",
      "bbox": [
        1279.5758056640625,
        1213.9554443359375,
        2342.704833984375,
        2336.692138671875
      ],
      "text": "0019/2016 viruses were tested in MN assays in year 1 using MDCK-SIAT1\ncells using methods as previously described44. In Year 2, egg- and cell-\npropagated A/Kansas/14/2017 viruses were tested by HI assays using\n0.75% guinea pig erythrocytes in the presence of 20 nM oseltamivir.\nEnzyme-linked immunosorbent assay (ELISA)\nTwenty percent of participants were selected by random sampling from\neach vaccine group and age strata (18−44 yrs and 45−64 yrs) in year 1\n(n = 144) and year 2 (n = 140), the MN/HI antibody levels of the subset are\nrepresentative of the whole study populations in year 1 (Fig. S3) and year\n2 (Fig. S4). These serum samples were tested by ELISA to evaluate the\ntotal binding antibodies against 8 recombinant HA proteins (rHA from\nboth egg-and cell-propagated viruses of each of the 4 vaccine antigens),\nand 2 rHA stalk proteins (A(H1N1)pdm09 HA stalk, and A(H3N2) HA\nstalk). rHA from egg- and cell A/Michigan/45/2015 (H1N1)pdm09, rHA\nhead from egg- and cell- A/Singapore/INFIMH-16-0019/2016 (H3N2), B/\nColorado/06/2017 (B/Victoria), and B/Phuket/3073/2013 (B/Yamagata)\nwere tested with year 1 sera; rHA from egg- A/Brisbane/02/2018 (H1N1)\npdm09 and cell-A/Idaho/7/2018 (H1N1)pdm09, rHA head from egg- and\ncell- A/Kansas/14/2017 (H3N2), egg- and cell- B/Colorado/06/2017 (B/\nVictoria), egg- and cell-B/Phuket/3073/2013 (B/Yamagata) were tested\nwith year 2 sera. The puriﬁed and trimeric recombinant HA proteins\nwere expressed from the baculovirus system using the established\nprocedures45. For ELISA, rHA antigens were coated at 100 ng/well. Serum\nsamples were tested at an initial dilution of 1:400 followed by 2-fold\ni l dil\ni\nA\nib di\nd\nd b\nh\ndi h\nid",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9746363162994385,
        "detection_dpi": 300
      }
    },
    {
      "id": "69fcfd26",
      "page_index": 10,
      "role": "Text",
      "bbox": [
        165.2261199951172,
        1620.4840087890625,
        1225.6087646484375,
        2291.939208984375
      ],
      "text": "ﬁndings from comparative immunogenicity studies and provide\nadditional information to identify optimal vaccination strategies to\nprevent inﬂuenza.\nMaterials and methods\nStudy design\nThe original study was a randomized, open-label trial conducted in the\nKPNW\n49\n40 45\n37\n136\n48 51\n26\nPrior inﬂuenza vaccination history\nReceipt of inﬂuenza vacicnes in\nall the last 5 seasons\n83\n68 93\n78\n209\n74\n135\n68\nPrior season\nvaccination(2017−2018)\n108\n89 104\n87\n245\n87\n176\n89",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9976903200149536,
        "detection_dpi": 300
      }
    },
    {
      "id": "b83ab4fe",
      "page_index": 10,
      "role": "Text",
      "bbox": [
        1274.13916015625,
        655.3377685546875,
        2331.63623046875,
        1146.6217041015625
      ],
      "text": "(HRP) conjugated goat anti human pan immunoglobulin conjugate to\ndetect total binding antibodies. ELISA was performed based on pre-\nviously described procedures46,47. The ELISA titers were determined as\nthe reciprocal of the highest dilution of serum samples that achieved an\noptical density (OD) value of 0.2 or greater.\nSequence analyses\nAll the testing viruses used in this study were sequenced. Sequences\nwere analyzed against the sequences of candidate vaccine viruses (CVV)\nof the study vaccines as deposited in Global Initiative on Sharing Avian\nInﬂuenza Data (GISAID) database by BioEdit version 7.0.9.0 (Table 1).",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9966652989387512,
        "detection_dpi": 300
      }
    },
    {
      "id": "0ef8476d",
      "page_index": 10,
      "role": "Text",
      "bbox": [
        167.0687255859375,
        2305.599853515625,
        1228.09814453125,
        2737.224365234375
      ],
      "text": "(11)\n(11)\n(11)\n(12)\nAge Group\n18−44 years\n57\n47\n55\n46 135\n48 99\n50\n45−64 years\n65\n53\n65\n54 148\n52 99\n50\nFemale\n107\n88\n103\n86 233\n82 157\n79\nWhite\n110\n90 94\n78\n232\n82 148\n75\nHispanic\n13\n11\n19\n16\n37\n13\n37\n19\nSite\nBSWH\n73\n60 75\n63 147\n52 147\n74",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9956430196762085,
        "detection_dpi": 300
      }
    },
    {
      "id": "23a8f5b2",
      "page_index": 10,
      "role": "Table",
      "bbox": [
        179.02813720703125,
        270.3605651855469,
        1227.677734375,
        1290.2635498046875
      ],
      "text": "[TABLE 2 - See table_p11_23a8f5b2.png]",
      "html": null,
      "image_path": "figures/table_p11_23a8f5b2.png",
      "metadata": {
        "score": 0.9291844964027405,
        "detection_dpi": 300
      }
    },
    {
      "id": "9d119dc7",
      "page_index": 10,
      "role": "Text",
      "bbox": [
        1266.791259765625,
        193.6947784423828,
        2334.40673828125,
        648.7839965820312
      ],
      "text": "Statistical analyses\nGeometric mean titers (GMTs) at day 0, 1-month and 6-months, geo-\nmetric mean fold rise (GMFR) of antibody titers at 1-month versus day\n0, and geometric mean fold reduction of antibody titers at 6 months\nversus 1-month were calculated per vaccine group. “GMT egg/cell titer\nratio” (ratio = GMT to egg-grown vaccine virus or rHA/GMT to cell-\ngrown vaccine virus or rHA) was calculated to quantify the difference\nin antibody response to egg- versus corresponding cell-propagated\nvaccine virus for each vaccine group. The proportion of participants",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.98887699842453,
        "detection_dpi": 300
      }
    },
    {
      "id": "f35fd0c1",
      "page_index": 10,
      "role": "Text",
      "bbox": [
        1271.2711181640625,
        2697.70947265625,
        2342.752197265625,
        3059.963134765625
      ],
      "text": "p\np g\ny\ny\ngg\ng\nA(H1N1)pdm09 and inﬂuenza B viruses were propagated in Madin-\nDarby canine kidney (MDCK) cells. Inﬂuenza B antigens were ether-\ntreated prior to use in the HI assays. Egg- and cell (MDCK)-propagated\nA/Michigan/45/2015 (H1N1)pdm09, B/Colorado/06/2017 (B/Victoria),\nand B/Phuket/3073/2013 (B/Yamagata) viruses were tested in year 1,\nEgg-propagated A/Brisbane/02/2018 (H1N1)pdm09, cell-propagated\nA/Idaho/7/2018 (H1N1)pdm09, egg- and cell-propagated B/Colorado/\n06/2017 (B/Victoria) and B/Phuket/3073/2013 (B/Yamagata) viruses",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9945598244667053,
        "detection_dpi": 300
      }
    },
    {
      "id": "4318fe21",
      "page_index": 10,
      "role": "Text",
      "bbox": [
        171.8299102783203,
        2878.299072265625,
        1224.668212890625,
        3054.582275390625
      ],
      "text": "Fluzone\nIIV4\nFluarix\nIIV4\nccIIV4\nRIV4\nn = 122\nn = 120\nn = 283\nn = 198",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9932950139045715,
        "detection_dpi": 300
      }
    },
    {
      "id": "d6cac7e8",
      "page_index": 10,
      "role": "Title",
      "bbox": [
        1271.9542236328125,
        2651.80908203125,
        1596.80908203125,
        2691.388671875
      ],
      "text": "were tested in year 2",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9970996379852295,
        "detection_dpi": 300
      }
    },
    {
      "id": "737010df",
      "page_index": 10,
      "role": "Title",
      "bbox": [
        1274.59912109375,
        2388.038330078125,
        1588.9022216796875,
        2429.78759765625
      ],
      "text": "MDCK cells with",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9952681660652161,
        "detection_dpi": 300
      }
    },
    {
      "id": "84050d1a",
      "page_index": 10,
      "role": "Title",
      "bbox": [
        168.309326171875,
        1530.9102783203125,
        650.696533203125,
        1614.3834228515625
      ],
      "text": "United States during the Norther\n2019−2020 (Year 2) inﬂuenza s",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9906976819038391,
        "detection_dpi": 300
      }
    },
    {
      "id": "cbd52d7f",
      "page_index": 10,
      "role": "Title",
      "bbox": [
        167.89892578125,
        2787.860107421875,
        1149.2921142578125,
        2868.270751953125
      ],
      "text": "n\n%\nn\n%\nn\n%\nn\nDemographic characteristics",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9837768077850342,
        "detection_dpi": 300
      }
    },
    {
      "id": "47080b9a",
      "page_index": 10,
      "role": "Text",
      "bbox": [
        1266.4395751953125,
        2432.71533203125,
        2344.188232421875,
        2611.514892578125
      ],
      "text": "y\np\ny\ny\nassays in year 1 (the cell-grown vaccine antigen of the study year does\nnot hemagglutinate in the HI assays), and HI assays in year 2. Egg-grown\nA(H3N2) viruses were propagated in 10-day-old embryonated chicken\neggs, cell-grown A(H3N2) viruses were propagated in stably transfected",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9665672183036804,
        "detection_dpi": 300
      }
    },
    {
      "id": "f914b67e",
      "page_index": 10,
      "role": "Text",
      "bbox": [
        172.67898559570312,
        1355.9569091796875,
        1225.845947265625,
        1490.893310546875
      ],
      "text": "blinding were previously described27–29. Participant characterisitcs in\nyear 1 are described in Table 2. During Year 1, HCP were stratiﬁed by two\nage groups (18−44 years and 45−64 years) and randomized at 4:4:2:2",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9180808067321777,
        "detection_dpi": 300
      }
    },
    {
      "id": "098b8989",
      "page_index": 10,
      "role": "Title",
      "bbox": [
        162.8179473876953,
        197.5352783203125,
        941.6268310546875,
        243.93746948242188
      ],
      "text": null,
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.6251863241195679,
        "detection_dpi": 300
      }
    },
    {
      "id": "30c0d979",
      "page_index": 11,
      "role": "List",
      "bbox": [
        170.236083984375,
        823.6700439453125,
        2326.950927734375,
        3109.591064453125
      ],
      "text": "with MN or HI GMT egg/cell titer ratio ≥4-fold was calculated to\nquantify the percent of participants with antibodies predominantly\ntargeting egg-adapted epitopes per vaccine group. One-way ANOVA\ncorrected for multiple comparisons (Tukey’s test) or nonparametric\nKruskal-Wallis test was used for multiple group comparison, two-tailed\npaired t test was used to compare pre- and post-vaccination; two-tailed\nunpaired t test was used to compare the post-vaccination titers\nbetween IIV4-IIV4 (Fluzone) arm and each of the remaining 6 arms in\nYear 2; Two-tailed Fisher’s exact test was used for comparing pro-\nportions. P < 0.05 is considered statistically signiﬁcant. SAS 9.4 (SAS\nInstitute) and GraphPad Prism 8 (GraphPad Software, Inc.) were used\nfor statistical analyses.\nEthic review\nThe study protocol was reviewed and approved by the institutional\nreview boards (IRBs) of the study sites and the Centers for Disease\nControl and Prevention. Informed consent was obtained from the par-\nticipants. This study is registered on ClinicalTrials.gov, NCT03722589.\nReporting summary\nFurther information on research design is available in the Nature\nPortfolio Reporting Summary linked to this article.\nData availability\nThe data that support the ﬁndings of this study are included in the\nmanuscript, supplementary information, and the ﬁgshare repository\nhttps://doi.org/10.6084/m9.ﬁgshare.22666231. Additional raw data\nfrom the study are available from the corresponding author (mlevi-\nne@cdc.gov) upon request.\nReferences\n1.\nFlannery, B. et al. Inﬂuenza vaccine effectiveness in the United\nStates during the 2016-2017 season. Clin. Infect. Dis. 68,\n1798–1806 (2019).\n2.\nLevine, M. Z. et al. Antibodies Against Egg- and Cell-Grown Inﬂu-\nenza A(H3N2) viruses in adults hospitalized during the 2017-2018\ninﬂuenza season. J. Infect. Dis. 219, 1904–1912 (2019).\n3.\nLiu, F. et al. Age-speciﬁc effects of vaccine egg adaptation and\nimmune priming on A(H3N2) antibody responses following inﬂu-\nenza vaccination. J. Clin. Investig. 131, e146138 (2021).\n4.\nRolfes, M. A. et al. Effects of Inﬂuenza Vaccination in the United\nStates During the 2017-2018 Inﬂuenza Season. Clin. Infect. Dis. 69,\n1845–1853 (2019).\n5.\nWu,N.C.et al.Astructuralexplanationfortheloweffectivenessofthe\nseasonal inﬂuenza H3N2 vaccine. PLoS Pathog. 13, e1006682 (2017).\n6.\nZost, S. J. et al. Contemporary H3N2 inﬂuenza viruses have a gly-\ncosylation site that alters binding of antibodies elicited by egg-\nadapted vaccine strains. Proc. Natl. Acad. Sci. USA 114,\n12578–12583 (2017).\n7.\nBarr, I. G. et al. Cell culture-derived inﬂuenza vaccines in the severe\n2017-2018 epidemic season: a step towards improved inﬂuenza\nsubunit inﬂuenza virus vaccines in healthy children: a phase III\nrandomized, multicenter, double-blind clinical trial. Int. J. Infect.\nDis. 41, 65–72 (2015).\n13.\nGouma, S. et al. Comparison of human H3N2 antibody responses\nelicited by egg-based, cell-based, and recombinant protein-based\ninﬂuenza vaccines during the 2017-2018 season. Clin. Infect. Dis. 71\n1447–1453 (2020).\n14.\nIzurieta, H. S. et al. Relative effectiveness of cell-cultured and egg\nbased inﬂuenza vaccines among elderly persons in the United\nStates, 2017-2018. J. Infect. Dis. 220, 1255–1264 (2019).\n15.\nDunkle, L. M. et al. Efﬁcacy of recombinant inﬂuenza vaccine in\nadults 50 years of age or older. N. Engl. J. Med. 376,\n2427–2436 (2017).\n16.\nBoikos, C., Sylvester, G. C., Sampalis, J. S. & Mansi, J. A. Relative\neffectiveness of the cell-cultured quadrivalent inﬂuenza vaccine\ncompared to standard, egg-derived quadrivalent inﬂuenza vac-\ncines in preventing inﬂuenza-like illness in 2017-2018. Clin. Infect.\nDis. 71, e665–e671 (2020).\n17.\nThompson, M. G. et al. Effects of repeated annual inactivated\ninﬂuenza vaccination among healthcare personnel on serum\nhemagglutinin inhibition antibody response to A/Perth/16/2009\n(H3N2)-like virus during 2010-11. Vaccine 34, 981–988 (2016).\n18.\nNabeshima, S. et al. Antibody response to inﬂuenza vaccine in\nadults vaccinated with identical vaccine strains in consecutive\nyears. J. Med. Virol. 79, 320–325 (2007).\n19.\nLeung, V. K. Y. et al. Inﬂuenza vaccination responses: evaluating\nimpact of repeat vaccination among health care workers. Vaccine\n35, 2558–2568 (2017).\n20. Khurana, S. et al. Repeat vaccination reduces antibody afﬁnity\nmaturation across different inﬂuenza vaccine platforms in humans\nNat. Commun. 10, 3338 (2019).\n21.\nKeitel, W. A., Cate, T. R., Couch, R. B., Huggins, L. L. & Hess, K. R.\nEfﬁcacy of repeated annual immunization with inactivated inﬂuenza\nvirus vaccines over a ﬁve year period. Vaccine 15, 1114–1122 (1997)\n22. Skowronski, D. M. et al. A perfect storm: impact of genomic varia-\ntion and serial vaccination on low inﬂuenza vaccine effectiveness\nduring the 2014-2015 season. Clin. Infect. Dis. 63, 21–32 (2016).\n23. Ohmit, S. E. et al. Inﬂuenza vaccine effectiveness in the 2011-2012\nseason: protection against each circulating virus and the effect of\nprior vaccination on estimates. Clin. Infect. Dis. 58, 319–327 (2014)\n24. Ohmit, S. E. et al. Inﬂuenza vaccine effectiveness in the community\nand the household. Clin. Infect. Dis. 56, 1363–1369 (2013).\n25. McLean, H. Q. et al. Impact of repeated vaccination on vaccine\neffectiveness against inﬂuenza A(H3N2) and B during 8 seasons.\nClin. Infect. Dis. 59, 1375–1385 (2014).\n26. Belongia, E. A. et al. Repeated annual inﬂuenza vaccination and\nvaccine effectiveness: review of evidence. Expert Rev. Vaccines 16\n1–14 (2017).\n27.\nDawood, F. S. et al. Comparison of the immunogenicity of cell\nculture-based and recombinant quadrivalent inﬂuenza vaccines to\nconventional egg-based quadrivalent inﬂuenza vaccines among",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9358267784118652,
        "detection_dpi": 300
      }
    },
    {
      "id": "3fcd9634",
      "page_index": 11,
      "role": "Title",
      "bbox": [
        165.9052734375,
        784.2820434570312,
        372.35601806640625,
        819.73583984375
      ],
      "text": "vaccine e",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9962455630302429,
        "detection_dpi": 300
      }
    },
    {
      "id": "69e0c5f5",
      "page_index": 11,
      "role": "Text",
      "bbox": [
        1362.66357421875,
        204.3828582763672,
        2296.279052734375,
        321.43951416015625
      ],
      "text": "WHO. Recommendations for inﬂuenza vaccine composition.\nhttps://www.who.int/teams/global-inﬂuenza-programme/\nvaccines/who-recommendations.).",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.8361397385597229,
        "detection_dpi": 300
      }
    },
    {
      "id": "ce414bf3",
      "page_index": 11,
      "role": "List",
      "bbox": [
        171.89515686035156,
        195.59388732910156,
        1270.77197265625,
        778.8705444335938
      ],
      "text": "8.\nDunkle, L. M. et al. Randomized comparison of immunogenicity and\nsafety of quadrivalent recombinant versus inactivated inﬂuenza\nvaccine in healthy adults 18-49 years of age. J. Infect. Dis. 216,\n1219–1226 (2017).\n9.\nDunkle, L. M. et al. Safety and immunogenicity of a recombinant\ninﬂuenza vaccine: a randomized trial. Pediatrics 141, e20173021 (2018).\n10.\nNolan, T. et al. Efﬁcacy of a cell-culture-derived quadrivalent inﬂu-\nenza vaccine in children. N. Engl. J. Med. 385, 1485–1495 (2021).\n11.\nMoehling, K. K. et al. A randomized controlled trial of antibody\nresponse to 2018-19 cell-based vs. egg-based quadrivalent inacti-\nvated inﬂuenza vaccine in children. Vaccine 38, 5171–5177 (2020).\n12.\nHartvickson, R. et al. Non-inferiority of mammalian cell-derived\nquadrivalent subunit inﬂuenza virus vaccines compared to trivalent",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.6105341911315918,
        "detection_dpi": 300
      }
    },
    {
      "id": "1bd7cf1d",
      "page_index": 12,
      "role": "List",
      "bbox": [
        165.84300231933594,
        109.13091278076172,
        2343.0927734375,
        2729.11669921875
      ],
      "text": "systematic review and meta-analysis. Lancet Respir. Med. 11,\n27–44 (2023).\n34. Shaw, M. W. et al. Reappearance and global spread of variants of\ninﬂuenza B/Victoria/2/87 lineage viruses in the 2000-2001 and\n2001-2002 seasons. Virology 303, 1–8 (2002).\n35. Saito, T. et al. Antigenic alteration of inﬂuenza B virus associated\nwith loss of a glycosylation site due to host-cell adaptation. J. Med.\nVirol. 74, 336–343 (2004).\n36. Robertson, J. S. et al. Alterations in the hemagglutinin associated\nwith adaptation of inﬂuenza B virus to growth in eggs. Virology 143,\n166–174 (1985).\n37. Raymond, D. D. et al. Inﬂuenza immunization elicits antibodies\nspeciﬁc for an egg-adapted vaccine strain. Nat. Med. 22,\n1465–1469 (2016).\n38. Liu, F. et al. Inﬂuence of immune priming and egg adaptation in the\nvaccine on antibody responses to circulating A(H1N1)pdm09 viru-\nses after inﬂuenza vaccination in adults. J. Infect. Dis. 218,\n1571–1581 (2018).\n39. Koel, B. F. et al. Identiﬁcation of amino acid substitutions supporting\nantigenic change of inﬂuenza A(H1N1)pdm09 viruses. J. Virol. 89,\n3763–3775 (2015).\n40. Koel, B. F. et al. Substitutions near the receptor binding site deter-\nmine major antigenic change during inﬂuenza virus evolution. Sci-\nence 342, 976–979 (2013).\n41.\nChen, Z. et al. Generation of live attenuated novel inﬂuenza virus A/\nCalifornia/7/09 (H1N1) vaccines with high yield in embryonated\nchicken eggs. J. Virol. 84, 44–51 (2010).\n42. Caton, A. J., Brownlee, G. G., Yewdell, J. W. & Gerhard, W. The\nantigenic structure of the inﬂuenza virus A/PR/8/34 hemagglutinin\n(H1 subtype). Cell 31, 417–427 (1982).\n43. Network WGIS. Manual for the laboratory diagnosis and virological\nsurveillance of inﬂuenza. https://iris.who.int/bitstream/handle/\n10665/44518/9789241548090_eng.pdf?sequence=1 (2011).\n44. Gross, F. L., Bai, Y., Jefferson, S., Holiday, C. & Levine, M. Z. Mea-\nsuring Inﬂuenza Neutralizing Antibody Responses to A(H3N2) Viru-\nses in Human Sera by Microneutralization Assays Using MDCK-SIAT1\nCells. J. Vis. Exp. 56448, https://doi.org/10.3791/56448 (2017).\n45. Stevens, J. et al. Structure of the uncleaved human H1 hemagglu-\ntinin from the extinct 1918 inﬂuenza virus. Science 303,\n1866–1870 (2004).\n46. Li, Z. N. et al. IgM, IgG, and IgA antibody responses to inﬂuenza\nA(H1N1)pdm09 hemagglutinin in infected persons during the ﬁrst\nwave of the 2009 pandemic in the United States. Clin. Vaccin.\nImmunol. 21, 1054–1060 (2014).\n47. Li, Z. N. et al. Serologic evidence of inﬂuenza A(H1N1)pdm09 virus\ninfection in northern sea otters. Emerg. Infect. Dis. 20, 915–917 (2014).\nAcknowledgements\nWe thank the staff from Baylor Scott & White Health and Kaiser Perma-\nnente Northwest for their participation and support of the study. We\nAuthor contributions\nM.Z.L., F.S.D., B.F., A.M.F., M.G.T., T.T., M.G. and A.L.N. were involved in\nthe conception and the design of the studies. F.L., F.L.G., S.J., K.M., H.G.,\nM.G.W., L.J.E., L.G., S.S.K., S.S., S.G., performed the studies and acquired\nthe data. F.L. and S.J. analyzed the data. F.L. and M.Z.L. wrote the\nmanuscript. M.Z.L. supervised the study. All co-authors were involved in\nmanuscript preparation process for important intellectual content.\nCompeting interests\nM.G.received funding from Pﬁzer for anunrelated educational grant and\nJanssen for an unrelated study. A.L.N. received research funding from\nPﬁzer and Vir Biotechnology for unrelated studies. All other authors\ndeclared no conﬂict of interest.\nAdditional information\nSupplementary information The online version contains\nsupplementary material available at\nhttps://doi.org/10.1038/s41467-023-44551-x.\nCorrespondence and requests for materials should be addressed to Min\nZ. Levine.\nPeer review information Nature Communications thanks Surender\nKhurana and the other, anonymous, reviewer(s) for their contribution to\nthe peer review of this work.\nReprints and permissions information is available at\nhttp://www.nature.com/reprints\nPublisher’s note Springer Nature remains neutral with regard to jur-\nisdictional claims in published maps and institutional afﬁliations.\nOpen Access This article is licensed under a Creative Commons\nAttribution 4.0 International License, which permits use, sharing,\nadaptation, distribution and reproduction in any medium or format, as\nlong as you give appropriate credit to the original author(s) and the\nsource, provide a link to the Creative Commons licence, and indicate if\nchanges were made. The images or other third party material in this\narticle are included in the article’s Creative Commons licence, unless\nindicated otherwise in a credit line to the material. If material is not\nincluded in the article’s Creative Commons licence and your intended\nuse is not permitted by statutory regulation or exceeds the permitted\nuse, you will need to obtain permission directly from the copyright\nholder. To view a copy of this licence, visit http://creativecommons.org/\nlicenses/by/4.0/.\n© This is a U.S. Government work and not under copyright protection in\nthe US; foreign copyright protection may apply 2024\n1Inﬂuenza Division, Centers for Disease Control and Prevention, Atlanta, GA, USA. 2Baylor Scott & White Health, Temple, TX, USA. 3Baylor College of Medicine,\nTemple, TX, USA. 4Texas A & M University, College of Medicine, Temple, TX, USA. 5Kaiser Permanente Northwest Center for Health Research, Portland,\nOR, USA. 6Abt Associates, Atlanta, GA, USA.\ne-mail: mlevine@cdc.gov\nN\nC\ni\ni\n| (2024)15 254\n13",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.968589186668396,
        "detection_dpi": 300
      }
    },
    {
      "id": "3406d211",
      "page_index": 12,
      "role": "Text",
      "bbox": [
        169.4974822998047,
        2890.910888671875,
        2311.89697265625,
        3022.7158203125
      ],
      "text": "States During the 2018 2019 Inﬂuenza Season. Clin. Infect. Dis. 71,\ne368–e376 (2020).\n32. Ramsay, L. C. et al. The impact of repeated vaccination on inﬂuenza\nvaccine effectiveness: a systematic review and meta-analysis BMC\nCDC for providing the recombinant HA proteins. We also thank Maked\nKay and Stacie Jefferson from inﬂuenza division of CDC for their assis\ntance with the study. Funding: This study was funded by the US Cente\nfor Disease Control and Prevention (contract 75D30118F02850) Dis-",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9895067811012268,
        "detection_dpi": 300
      }
    }
  ],
  "metadata": {
    "detection_dpi": 300,
    "total_pages": 13,
    "merge_settings": {
      "merge_overlapping": true,
      "merge_threshold": 0.3,
      "confidence_weight": 0.7,
      "area_weight": 0.3
    },
    "extraction": {
      "text_blocks": 90,
      "figure_blocks": 10,
      "figures_dir": "/Users/saul/projects/solstice/solstice/data/cache/Liu_et_al.__2024_/extracted/figures"
    }
  },
  "reading_order": [
    [
      "0daf2127",
      "36f5ef49",
      "780f7477",
      "ad024964",
      "322dfb5c",
      "91229ccc"
    ],
    [
      "b42ff5e7",
      "5605b8d5",
      "3b1dc510",
      "73c97565",
      "8d91b87c",
      "bc31ebbf",
      "151f2b8c",
      "5e27dfe8"
    ],
    [
      "09247097",
      "0702adab",
      "d474d613",
      "ede7e14c",
      "4606bbf6",
      "feac388e",
      "827ebba1",
      "b957e0e3"
    ],
    [
      "f4865143",
      "9c019275",
      "75c30643",
      "b1615215",
      "aeb5ab4a",
      "142898bc",
      "cf295da8"
    ],
    [
      "dca5161e",
      "ea97191d",
      "9da929bc",
      "609127ac",
      "cb53abc9",
      "88398e9b",
      "c6e3596b",
      "7e8872b4",
      "8ed5be8f",
      "11172f20",
      "72ba682a",
      "b35cb547"
    ],
    [
      "b0a88f0c",
      "69f7ff84",
      "62c80c9f",
      "ad9f2327",
      "579d38c9",
      "b3a95400",
      "c409ac0c",
      "aab3768e",
      "ca5a2586",
      "6b103e88",
      "a2bfedeb"
    ],
    [
      "d52355c3",
      "fb8e6c04",
      "9d981e40",
      "b2ed3635",
      "5cf6ea89",
      "0f7cc72a",
      "a6a42178",
      "5e27d60f",
      "e3cddf12"
    ],
    [
      "fe11606f",
      "86998ed0",
      "876e133f",
      "2465f363",
      "a13f3437",
      "7360231c",
      "82e72e9a",
      "a94db619"
    ],
    [
      "607ba538",
      "96a180f1",
      "0040f8f5",
      "2a45e33d",
      "7c01762d",
      "1310697f",
      "09e2fed5"
    ],
    [
      "90bee6e4",
      "68d47cb0",
      "fa38b393",
      "10c518cc",
      "ce1e37d3",
      "bcb4fe5b",
      "586b09ff",
      "cb9c94ec"
    ],
    [
      "098b8989",
      "23a8f5b2",
      "f914b67e",
      "84050d1a",
      "69fcfd26",
      "0ef8476d",
      "cbd52d7f",
      "4318fe21",
      "9d119dc7",
      "b83ab4fe",
      "3d6e6a6b",
      "737010df",
      "47080b9a",
      "d6cac7e8",
      "f35fd0c1"
    ],
    [
      "ce414bf3",
      "3fcd9634",
      "30c0d979",
      "69e0c5f5"
    ],
    [
      "1bd7cf1d",
      "3406d211"
    ]
  ]
}